Nosis Bio to Present Accepted Abstract on RNA Medicine for Pulmonary Disease at the 2024 European Respiratory Symposium

Nosis Biosciences has been accepted to present a poster at the 2024 European Respiratory Symposium, showcasing our latest research in RNA-based therapies. This marks a significant milestone for Nosis Bio as we present data on the pre-clinical development of a novel RNA medicine designed specifically for pulmonary diseases.

Our poster, based on extensive pre-clinical work, will highlight the potential of our cell and gene-specific RNA medicine in targeting the underlying drivers of lung disease. This therapy leverages Nosis Bio’s proprietary physics-aware deep learning platform, which allows for precise targeting at the cellular level, aiming to enhance efficacy and reduce off-target effects. By honing in on pathogenic cells and genes associated with pulmonary disease, our approach aspires to offer a new, more precise treatment pathway in the field of respiratory medicine.

The 2024 European Respiratory Symposium provides an excellent platform to connect with leading scientists and clinicians in pulmonary research. We look forward to engaging with the broader scientific community, sharing insights from our development program, and discussing how AI-driven RNA therapies could bring transformative options to patients suffering from respiratory conditions.

Stay tuned for updates from the symposium as Nosis Bio continues its commitment to advancing RNA medicines and pioneering precision-targeted treatments for pulmonary disease.

‍